Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Novartis
US Department of Justice
Daiichi Sankyo
Express Scripts
McKesson
Dow
Citi
Teva
US Army

Generated: October 17, 2017

DrugPatentWatch Database Preview

GANIRELIX ACETATE Drug Profile

« Back to Dashboard

Which patents cover Ganirelix Acetate, and what generic Ganirelix Acetate alternatives are available?

Ganirelix Acetate is a drug marketed by Organon Usa Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has seven patent family members in seven countries and four supplementary protection certificates in four countries.

The generic ingredient in GANIRELIX ACETATE is ganirelix acetate. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ganirelix acetate profile page.

Summary for Tradename: GANIRELIX ACETATE

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list956
Drug Prices:see details
DailyMed Link:GANIRELIX ACETATE at DailyMed

Pharmacology for Tradename: GANIRELIX ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Usa Inc
GANIRELIX ACETATE
ganirelix acetate
INJECTABLE;INJECTION021057-001Jul 29, 1999RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: GANIRELIX ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon Usa Inc
GANIRELIX ACETATE
ganirelix acetate
INJECTABLE;INJECTION021057-001Jul 29, 1999► Subscribe► Subscribe
Organon Usa Inc
GANIRELIX ACETATE
ganirelix acetate
INJECTABLE;INJECTION021057-001Jul 29, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for GANIRELIX ACETATE

Drugname Dosage Strength RLD Submissiondate
ganirelix acetateInjection250 mcg/0.5 mL, 1 mL PFSGanirelix Acetate3/30/2012

International Patent Family for Tradename: GANIRELIX ACETATE

Country Document Number Estimated Expiration
Denmark0994718► Subscribe
Australia8727798► Subscribe
Spain2247710► Subscribe
Austria302018► Subscribe
Germany69831241► Subscribe
World Intellectual Property Organization (WIPO)9858657► Subscribe
European Patent Office0994718► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: GANIRELIX ACETATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00016Netherlands► SubscribePRODUCT NAME: GANIRELIX, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/00/130/001-002 20000517
00C/030Belgium► SubscribePRODUCT NAME: GANIRELIX; REGISTRATION NO/DATE: EU/1/00/130/001 20000518
C/GB00/024United Kingdom► SubscribePRODUCT NAME: GANIRELIX OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/130/001 20000517; UK EU/1/00/130/002 20000517
/2000Austria► SubscribePRODUCT NAME: GANIRELIX ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/00/130/001-002 20000517
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Merck
Dow
Novartis
Daiichi Sankyo
Harvard Business School
Teva
QuintilesIMS
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot